rifaximin and nitazoxanide

rifaximin has been researched along with nitazoxanide* in 1 studies

Other Studies

1 other study(ies) available for rifaximin and nitazoxanide

Article	Year
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:1 Rifaximin, ampicillin-sulbactam, neomycin, nitazoxanide, teicoplanin, and vancomycin were tested against 536 strains of anaerobic bacteria. The overall MIC of rifaximin at which 50% of strains were inhibited was 0.25 microg/ml. Ninety percent of the strains tested were inhibited by 256 microg/ml of rifaximin or less, an activity equivalent to those of teicoplanin and vancomycin but less than those of nitazoxanide and ampicillin-sulbactam. Topics: Ampicillin; Bacteria, Anaerobic; Feces; Microbial Sensitivity Tests; Neomycin; Nitro Compounds; Rifamycins; Rifaximin; Sulbactam; Teicoplanin; Thiazoles; Vancomycin	2009

Article

Year

Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.

Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:1

Rifaximin, ampicillin-sulbactam, neomycin, nitazoxanide, teicoplanin, and vancomycin were tested against 536 strains of anaerobic bacteria. The overall MIC of rifaximin at which 50% of strains were inhibited was 0.25 microg/ml. Ninety percent of the strains tested were inhibited by 256 microg/ml of rifaximin or less, an activity equivalent to those of teicoplanin and vancomycin but less than those of nitazoxanide and ampicillin-sulbactam.

Topics: Ampicillin; Bacteria, Anaerobic; Feces; Microbial Sensitivity Tests; Neomycin; Nitro Compounds; Rifamycins; Rifaximin; Sulbactam; Teicoplanin; Thiazoles; Vancomycin

2009